BridgeBio Oncology Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On August 11, 2025, immediately prior to the closing of the de-SPAC Transaction, Helix issued and sold to certain qualified institutional buyers, institutional accredited investors and other accredited investors an aggregate of 24,343,711 shares of its common stock, for a purchase price of $10.7173 per share and an aggregate purchase price of $260.9 million, pursuant to separate subscription agreements entered into and effective as of February 28, 2025. The issuance was made in a transaction not involving a public offering pursuant to an exemption from the registration requirements of the Securities Act in reliance upon Section 4(a)(2) of the Securities Act. The issuance was subsequently registered on a registration statement on Form S-1 with the SEC, which was declared effective on September 10, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.